Alvotech Entered into Commercialization Agreement with Advanz Pharma for AVT23, a Proposed Biosimilar to Xolair (omalizumab)
Shots:
- The companies collaborated to commercialize AVT23, a proposed biosimilar to Xolair (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand
- Alvotech will be responsible for the development and manufacture while Advanz Pharma will be responsible for the registration and commercialization. The agreement focuses to provide patients access to more affordable biologics globally
- Alvotech collaborated with BiosanaPharma in Feb 2022 for the co-development of AVT23. Omalizumab, an Ab targeting free IgE & is indicated to treat patients with allergic asthma, chronic spontaneous urticaria, and nasal polyps
Ref: Globenewswire | Image: Alvotech
Click here to read the full press release
